GENMAB A/S -SP ADR (GMAB) Fundamental Analysis & Valuation

NASDAQ:GMAB • US3723032062

Current stock price

26.52 USD
+0.41 (+1.57%)
At close:
25.99 USD
-0.53 (-2%)
After Hours:

This GMAB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. GMAB Profitability Analysis

1.1 Basic Checks

  • In the past year GMAB was profitable.
  • GMAB had a positive operating cash flow in the past year.
  • In the past 5 years GMAB has always been profitable.
  • GMAB had a positive operating cash flow in each of the past 5 years.
GMAB Yearly Net Income VS EBIT VS OCF VS FCFGMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 7.48%, GMAB belongs to the top of the industry, outperforming 92.23% of the companies in the same industry.
  • GMAB's Return On Equity of 16.47% is amongst the best of the industry. GMAB outperforms 93.79% of its industry peers.
  • The Return On Invested Capital of GMAB (9.04%) is better than 92.82% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for GMAB is significantly below the industry average of 28.06%.
Industry RankSector Rank
ROA 7.48%
ROE 16.47%
ROIC 9.04%
ROA(3y)12.49%
ROA(5y)13.54%
ROE(3y)17.43%
ROE(5y)17.15%
ROIC(3y)12.48%
ROIC(5y)13.32%
GMAB Yearly ROA, ROE, ROICGMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20 25

1.3 Margins

  • GMAB has a Profit Margin of 25.89%. This is amongst the best in the industry. GMAB outperforms 93.59% of its industry peers.
  • In the last couple of years the Profit Margin of GMAB has declined.
  • GMAB has a Operating Margin of 33.60%. This is amongst the best in the industry. GMAB outperforms 96.12% of its industry peers.
  • GMAB's Operating Margin has declined in the last couple of years.
  • With an excellent Gross Margin value of 93.60%, GMAB belongs to the best of the industry, outperforming 94.37% of the companies in the same industry.
  • In the last couple of years the Gross Margin of GMAB has declined.
Industry RankSector Rank
OM 33.6%
PM (TTM) 25.89%
GM 93.6%
OM growth 3Y-7.78%
OM growth 5Y-11.4%
PM growth 3Y-11.69%
PM growth 5Y-11.27%
GM growth 3Y-2.18%
GM growth 5YN/A
GMAB Yearly Profit, Operating, Gross MarginsGMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. GMAB Health Analysis

2.1 Basic Checks

  • GMAB has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for GMAB has been reduced compared to 1 year ago.
  • The number of shares outstanding for GMAB has been reduced compared to 5 years ago.
  • Compared to 1 year ago, GMAB has a worse debt to assets ratio.
GMAB Yearly Shares OutstandingGMAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
GMAB Yearly Total Debt VS Total AssetsGMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

2.2 Solvency

  • An Altman-Z score of 2.58 indicates that GMAB is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of GMAB (2.58) is better than 67.38% of its industry peers.
  • The Debt to FCF ratio of GMAB is 4.80, which is a neutral value as it means it would take GMAB, 4.80 years of fcf income to pay off all of its debts.
  • GMAB has a Debt to FCF ratio of 4.80. This is amongst the best in the industry. GMAB outperforms 91.65% of its industry peers.
  • GMAB has a Debt/Equity ratio of 0.88. This is a neutral value indicating GMAB is somewhat dependend on debt financing.
  • GMAB's Debt to Equity ratio of 0.88 is on the low side compared to the rest of the industry. GMAB is outperformed by 74.76% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF 4.8
Altman-Z 2.58
ROIC/WACC1.45
WACC6.25%
GMAB Yearly LT Debt VS Equity VS FCFGMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B

2.3 Liquidity

  • GMAB has a Current Ratio of 2.02. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
  • GMAB has a Current ratio of 2.02. This is in the lower half of the industry: GMAB underperforms 77.67% of its industry peers.
  • A Quick Ratio of 2.01 indicates that GMAB has no problem at all paying its short term obligations.
  • The Quick ratio of GMAB (2.01) is worse than 76.31% of its industry peers.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 2.01
GMAB Yearly Current Assets VS Current LiabilitesGMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. GMAB Growth Analysis

3.1 Past

  • GMAB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.61%.
  • Measured over the past years, GMAB shows a quite strong growth in Earnings Per Share. The EPS has been growing by 9.47% on average per year.
  • Looking at the last year, GMAB shows a quite strong growth in Revenue. The Revenue has grown by 19.25% in the last year.
  • GMAB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.19% yearly.
EPS 1Y (TTM)-2.61%
EPS 3Y13.49%
EPS 5Y9.47%
EPS Q2Q%-75.02%
Revenue 1Y (TTM)19.25%
Revenue growth 3Y21.97%
Revenue growth 5Y19.19%
Sales Q2Q%14.88%

3.2 Future

  • Based on estimates for the next years, GMAB will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.95% on average per year.
  • GMAB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.44% yearly.
EPS Next Y-27.83%
EPS Next 2Y0.46%
EPS Next 3Y15.01%
EPS Next 5Y9.95%
Revenue Next Year18.39%
Revenue Next 2Y17.21%
Revenue Next 3Y16.79%
Revenue Next 5Y13.44%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GMAB Yearly Revenue VS EstimatesGMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
GMAB Yearly EPS VS EstimatesGMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

6

4. GMAB Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 15.15, the valuation of GMAB can be described as correct.
  • Based on the Price/Earnings ratio, GMAB is valued cheaper than 95.73% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 26.77, GMAB is valued a bit cheaper.
  • The Price/Forward Earnings ratio is 20.95, which indicates a rather expensive current valuation of GMAB.
  • Based on the Price/Forward Earnings ratio, GMAB is valued cheaply inside the industry as 94.17% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 21.75, GMAB is valued at the same level.
Industry RankSector Rank
PE 15.15
Fwd PE 20.95
GMAB Price Earnings VS Forward Price EarningsGMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, GMAB is valued cheaper than 93.79% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 96.89% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 14.4
EV/EBITDA 15.13
GMAB Per share dataGMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

  • The decent profitability rating of GMAB may justify a higher PE ratio.
  • A more expensive valuation may be justified as GMAB's earnings are expected to grow with 15.01% in the coming years.
PEG (NY)N/A
PEG (5Y)1.6
EPS Next 2Y0.46%
EPS Next 3Y15.01%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GMAB Dividend Analysis

5.1 Amount

  • GMAB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GMAB Fundamentals: All Metrics, Ratios and Statistics

GENMAB A/S -SP ADR

NASDAQ:GMAB (4/30/2026, 8:00:02 PM)

After market: 25.99 -0.53 (-2%)

26.52

+0.41 (+1.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)02-18
Earnings (Next)05-07
Inst Owners43.37%
Inst Owner Change-0.16%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap16.28B
Revenue(TTM)3.72B
Net Income(TTM)963.00M
Analysts74.07
Price Target34.46 (29.94%)
Short Float %1.35%
Short Ratio4.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.37%
Min EPS beat(2)-39.11%
Max EPS beat(2)36.36%
EPS beat(4)3
Avg EPS beat(4)18.01%
Min EPS beat(4)-39.11%
Max EPS beat(4)49.64%
EPS beat(8)6
Avg EPS beat(8)33.48%
EPS beat(12)8
Avg EPS beat(12)19.29%
EPS beat(16)11
Avg EPS beat(16)25.94%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.19%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.97%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.09%
Revenue beat(8)6
Avg Revenue beat(8)225.98%
Revenue beat(12)10
Avg Revenue beat(12)350.6%
Revenue beat(16)14
Avg Revenue beat(16)264.87%
PT rev (1m)-74.6%
PT rev (3m)-74.6%
EPS NQ rev (1m)-27.81%
EPS NQ rev (3m)-65.08%
EPS NY rev (1m)-14.77%
EPS NY rev (3m)-25.64%
Revenue NQ rev (1m)0.71%
Revenue NQ rev (3m)0.45%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)0.85%
Valuation
Industry RankSector Rank
PE 15.15
Fwd PE 20.95
P/S 4.38
P/FCF 14.4
P/OCF 13.73
P/B 2.78
P/tB N/A
EV/EBITDA 15.13
EPS(TTM)1.75
EY6.6%
EPS(NY)1.27
Fwd EY4.77%
FCF(TTM)1.84
FCFY6.95%
OCF(TTM)1.93
OCFY7.28%
SpS6.06
BVpS9.52
TBVpS-5.91
PEG (NY)N/A
PEG (5Y)1.6
Graham Number19.3653 (-26.98%)
Profitability
Industry RankSector Rank
ROA 7.48%
ROE 16.47%
ROCE 10.92%
ROIC 9.04%
ROICexc 10.63%
ROICexgc 409.04%
OM 33.6%
PM (TTM) 25.89%
GM 93.6%
FCFM 30.4%
ROA(3y)12.49%
ROA(5y)13.54%
ROE(3y)17.43%
ROE(5y)17.15%
ROIC(3y)12.48%
ROIC(5y)13.32%
ROICexc(3y)44.94%
ROICexc(5y)57.79%
ROICexgc(3y)214.92%
ROICexgc(5y)161.21%
ROCE(3y)15.08%
ROCE(5y)16.09%
ROICexgc growth 3Y67.71%
ROICexgc growth 5Y24.23%
ROICexc growth 3Y-49.91%
ROICexc growth 5Y-39%
OM growth 3Y-7.78%
OM growth 5Y-11.4%
PM growth 3Y-11.69%
PM growth 5Y-11.27%
GM growth 3Y-2.18%
GM growth 5YN/A
F-Score4
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.88
Debt/FCF 4.8
Debt/EBITDA 3.89
Cap/Depr 77.46%
Cap/Sales 1.48%
Interest Coverage 125
Cash Conversion 89.78%
Profit Quality 117.45%
Current Ratio 2.02
Quick Ratio 2.01
Altman-Z 2.58
F-Score4
WACC6.25%
ROIC/WACC1.45
Cap/Depr(3y)92.84%
Cap/Depr(5y)93.54%
Cap/Sales(3y)1.72%
Cap/Sales(5y)2.07%
Profit Quality(3y)124.53%
Profit Quality(5y)101.27%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.61%
EPS 3Y13.49%
EPS 5Y9.47%
EPS Q2Q%-75.02%
EPS Next Y-27.83%
EPS Next 2Y0.46%
EPS Next 3Y15.01%
EPS Next 5Y9.95%
Revenue 1Y (TTM)19.25%
Revenue growth 3Y21.97%
Revenue growth 5Y19.19%
Sales Q2Q%14.88%
Revenue Next Year18.39%
Revenue Next 2Y17.21%
Revenue Next 3Y16.79%
Revenue Next 5Y13.44%
EBIT growth 1Y24.57%
EBIT growth 3Y12.48%
EBIT growth 5Y5.6%
EBIT Next Year-3.74%
EBIT Next 3Y18.03%
EBIT Next 5Y4.98%
FCF growth 1Y4.43%
FCF growth 3Y30.57%
FCF growth 5Y3.84%
OCF growth 1Y5.23%
OCF growth 3Y28.97%
OCF growth 5Y3.81%

GENMAB A/S -SP ADR / GMAB Fundamental Analysis FAQ

What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?

ChartMill assigns a fundamental rating of 6 / 10 to GMAB.


What is the valuation status for GMAB stock?

ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.


What is the profitability of GMAB stock?

GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.


What is the earnings growth outlook for GENMAB A/S -SP ADR?

The Earnings per Share (EPS) of GENMAB A/S -SP ADR (GMAB) is expected to decline by -27.83% in the next year.